Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 6, 2014, Pages 1258-1264

  Wu, Jing Yuan J ^a   Shadbolt, Bruce ^b   Teoh, Narci ^a   Blunn, Anne ^a   To, Caroline ^a   Rodriguez Morales, Ilys ^a   Chitturi, Shivakumar ^a   Kaye, Graham ^a   Rodrigo, Kalyana ^b   Farrell, Geoff ^a  

^a Canberra Hospital   (Australia)

^b CANBERRA HOSPITAL   (Australia)

Author keywords

Bipolar affective disorder; Depression; Interferon based treatment; Multivariate analysis; Neuropsychiatric complications; Psychological comorbidity; Schizophrenia; Treatment adverse effects; Treatment uptake

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; BIPOLAR DISORDER; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG TOLERANCE; DRUG UPTAKE; FEMALE; HEPATITIS C; HUMAN; LIAISON PSYCHIATRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIST; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT WITHDRAWAL; CHEMICALLY INDUCED; COMPLICATION; DISEASE COURSE; MENTAL DISEASE; MIDDLE AGED; MULTIVARIATE ANALYSIS;

ADULT; ANTIVIRAL AGENTS; DEPRESSION; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MENTAL DISORDERS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RIBAVIRIN; SCHIZOPHRENIA;

EID: 84900543113     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12515     Document Type: Article

References (37)

1. Teoh NC, Farrell GC, Chan HL. Individualisation of antiviral therapy for chronic hepatitis C. J. Gastroenterol. Hepatol. 2010; 25: 1206-1216.
2. Maher L. Tackling hepatitis C in Australia: the third national strategy. Lancet Infect. Dis. 2012; 12: 172-173.
3. Gidding HF, Topp L, Middleton M etal. The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006. J. Gastroenterol. Hepatol. 2009; 24: 1648-1654.
4. Rosenberg SD, Goodman LA, Osher FC etal. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am. J. Public Health 2001; 91: 31-37.
5. Rosenberg SD, Drake RE, Brunette MF. Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS 2005; 19: S26-33.
6. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-982.
7. Hadziyannis SJ, Sette H Jr, Morgan TR etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 346-355.
8. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
9. Schaefer M, Hinzpeter A, Mohmand A etal. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46: 991-998.
10. Raison CL, Demetrashvili M, Capuron L etal. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19: 105-123.
11. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am. J. Psychiatry 2000; 157: 867-876.
12. Ward RP, Kugelmas M, Libsch KD. Management of hepatitis C: evaluating suitability for drug therapy. Am. Fam. Physician 2004; 69: 1429-1436.
13. Zdilar D, Franco-Bronson K, Buchler N etal. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 1207-1211.
14. Asnis GM, De La Garza R 2nd. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J. Clin. Gastroenterol. 2006; 40: 322-335.
15. Asnis GM, De La Garza R 2nd. Interferon-induced depression: strategies in treatment. Prog. Neuropsychopharmacol Biol. Psychiatry 2005; 29: 808-818.
16. Sockalingam S, Shammi C, Stergiopoulos V. Managing the neuropsychiatric complications of hepatitis C treatment. Br. J. Hosp. Med. (Lond.) 2007; 68: 520-525.
17. Crone CC, Gabriel GM, Wise TN. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve. Clin. J. Med. 2004; 71: S27-32.
18. Neri S, Bertino G, Petralia A etal. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. J. Clin. Gastroenterol. 2010; 44: e210-217.
19. Mistler LA, Brunette MF, Marsh BJ etal. Hepatitis C treatment for people with severe mental illness. Psychosomatics 2006; 47: 93-107.
20. Kelly EM, Corace K, Emery J etal. Bipolar patients can safely and successfully receive interferon-based hepatitis C antiviral treatment. Eur. J. Gastroenterol. Hepatol. 2012; 24: 811-816.
21. Fuller BE, Rodriguez VL, Linke A etal. Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. Gen. Hosp. Psychiatry 2011; 33: 232-237.
22. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-244.
23. Slade T, Johnston A, Oakley Browne MA etal. 2007 National Survey of Mental Health and Wellbeing: methods and key findings. Aust. N. Z. J. Psychiatry 2009; 43: 594-605.
24. Saha S, Chant D, Welham J etal. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005; 2: e141.
25. Perala J, Suvisaari J, Saarni SI etal. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 2007; 64: 19-28.
26. Australian Government Department of Health and Ageing. Third National Hepatitis C Strategy 2010-2013, 2010. Cited 6 May 2012. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-national-strategies-2010-hcv
27. Iskandar S, Kamal R, De Jong CA. Psychiatric comorbidity in injecting drug users in Asia and Africa. Curr. Opin. Psychiatry 2012; 25: 213-218.
28. Huckans MS, Blackwell AD, Harms TA etal. Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders. Psychiatr. Serv. 2006; 57: 403-406.
29. Edlin BR, Kresina TF, Raymond DB etal. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin. Infect. Dis. 2005; 40: S276-285.
30. Chainuvati S, Khalid SK, Kancir S etal. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. J. Viral Hepat. 2006; 13: 235-241.
31. Ho CJ, Preston C, Fredericks K etal. A unique model for treating chronic hepatitis C in patients with pschiatric disorders, substance abuse, and/or housing instability. J. Addict. Med. 2013; 7: 320-324.
32. Carrion JA, Gonzalez-Colominas E, Garcia-Retortillo M etal. A multidisciplinary support programme increases the efficiency of interferon alfa-2a and ribavirin in hepatitis C. J. Hepatol. 2013; 59: 926-933.
33. Malaguarnera M, Vacante M, Bertino G etal. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin. J. Interferon Cytokine Res. 2011; 31: 653-659.
34. Huckans M, Mitchell A, Pavawalla S etal. The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia. Antivir. Ther. 2010; 15: 111-119.
35. Huckans M, Mitchell A, Ruimy S etal. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr. Bull. 2010; 36: 165-172.
36. Eaton WW, Neufeld K, Chen LS etal. A comparison of self-report and clinical diagnostic interviews for depression: diagnostic interview schedule and schedules for clinical assessment in neuropsychiatry in the Baltimore epidemiologic catchment area follow-up. Arch. Gen. Psychiatry 2000; 57: 217-222.
37. Wright IA. Monitoring depression in patients undergoing alpha-interferon and ribavirin therapy for hepatitis C. Gastroenterol. Nurs. 2000; 23: 275-280.